Trial · NCT05971758
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
NCT05971758, Phase 2, Recruiting, University of California, Los Angeles
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease. Trials, record NCT05971758. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05971758
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
- NCT number
- NCT05971758
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- University of California, Los Angeles
- Conditions
- Cushing Disease
- Interventions
- Fimepinostat
- First posted
- 2023-08-02
- Last updated
- 2026-07-17
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with mUFC ≤ 1.0xULN | Baseline, 4 weeks | 4 week UFC calculated as the mean of three 24h UFC specimens collected on consecutive days between day 24-28 |
| Secondary | Number of participants with normalization (values within normal limits) or >50% improvement from baseline in 24h UFC, plasma ACTH, serum and salivary cortisol levels | Baseline, 4 weeks | 4 week UFC calculated as the mean of three 24h UFC specimens collected on consecutive days between day 24-28 |
| Secondary | body weight change from baseline | Baseline, Day 28 | |
| Secondary | body mass index change from baseline | Baseline, Day 28 | |
| Secondary | Systolic and Diastolic Blood Pressure Change from baseline | Baseline, Day 28 | |
| Secondary | Cushing Disease health-related quality of life questionnaire (CushingQoL) change from baseline | Baseline, Day 28 | The CushingQoL is scored using a total score ranging from 0 to 100 with lower scores indicating a greater impact on QoL |
| Secondary | Beck Depression inventory second edition (BDIII) change from baseline | Baseline, Day 28 | Beck Depression scale is scored as follows 1-10 These ups and downs are considered normal. 11-16 Mild mood disturbances. 17-20 borderline clinical depression. 21-30 Moderate depression. 31-40 Severe depression |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01FD007548 | Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease (IND 168501 - 07/31/2023) | HEANEY, ANTHONY P | UNIVERSITY OF CALIFORNIA LOS ANGELES | FOOD AND DRUG ADMINISTRATION | 2024 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05971758
GET https://conductscience.org/api/trials/v1/NCT05971758/registered